Emerging strategies, applications and challenges of targeting NAD + in the clinic.
Level 5 - mechanism / opinion, no new human data
Narrative review of clinical and translational studies without systematic search methodology
PubMed 40926126 · doi:10.1038/s43587-025-00947-6
What was done
This narrative review summarizes clinical trial evidence regarding the safety, bioavailability, and efficacy of NAD+-targeted interventions, focusing on aging and neurodegenerative diseases. It reviews established precursors (nicotinic acid, nicotinamide), newer compounds (nicotinamide riboside, nicotinamide mononucleotide), emerging precursor molecules, and supporting manufacturing and detection technologies.
What was found
The abstract reports no numerical findings, effect sizes, or study counts. It notes qualitatively that while NAD+ targets show clinical potential, optimal doses, administration routes, treatment frequencies, long-term safety, and sources of interindividual response variability remain to be defined in larger studies.
Why it matters
It provides a high-level overview of the translational landscape and practical challenges for testing NAD+ precursor therapies in human aging and neurodegeneration.
Limits
As a narrative review, it lacks a systematic literature search, formal risk-of-bias grading, and quantitative data synthesis. The abstract provides no primary data, participant totals, or specific clinical efficacy outcomes.
Cited by
- supports Nicotinamide mononucleotide (NMN) alters the epigenome and modulates the immune system.